Michael Leahy

7.3k citations

70 papers · 3.4k indexed · 3 hit papers · h-index 27

Impact in

Oncology top 1%
- Vascular Tumors and Angiosarcomas
- Cancer Immunotherapy and Biomarkers
Pulmonary and Respiratory Medicine top 1%
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes

Papers in

Gastroenterology 17
- Gastrointestinal Tumor Research and Treatment 17
Pulmonary and Respiratory Medicine 40
- Sarcoma Diagnosis and Treatment 29
- Gastric Cancer Management and Outcomes 9

Co-authors: Sandrine Marréaud Jean‐Yves Blay J. Martijn Kerst Jaap Verweij Pancras C.W. Hogendoorn Axel Le Cesne Maria De Santis Richard Sylvester
Journals: Journal of Clinical Oncology (18 papers)European Journal of Cancer (10 papers)Annals of Oncology (5 papers)British Journal of Cancer (4 papers)Sarcoma (3 papers)
Partner nations: United Kingdom France Netherlands

In The Last Decade

Michael Leahy

68 papers receiving 3.4k citations

Hit Papers

align trajectories log scale

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial 2017 · 340 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 The Lancet Oncology
2012 The Lancet Oncology
2011 Journal of Clinical Oncology

Peers

Countries citing papers authored by Michael Leahy

Since Specialization

Citations

This map shows the geographic impact of Michael Leahy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Leahy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Leahy more than expected).

Fields of papers citing papers by Michael Leahy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Leahy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Leahy. The network helps show where Michael Leahy may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Leahy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Leahy Line = papers co-authored together Michael Leahy links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma British Journal of Cancer ·Zhen Zhang, B. Bibby, Lingjian Yang, Brian R. Lane, Joely J. Irlam, Hitesh Mistry, Ella M Robertson, Helen Valentine, James Wylie, Patrick Shenjere, Michael Leahy, Piers Gaunt, Lucinda Billingham, Beatrice Seddon, Tadeusz Wielecki, Martin Robinson, Ananya Choudhury, Catharine West	2023	4
2	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 “CREATE” Trial International Journal of Molecular Sciences ·E Minguez, Elodie Modave, Bram Boeckx, Bernd Kasper, Steinar Aamdal, Michael Leahy, Piotr Rutkowski, Sebastian Bauer, Maria Dêbiec‐Rychter, Raf Sciot, Diether Lambrechts, Agnieszka Woźniak, Patrick Schöffski	2022	5
3	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE European Journal of Cancer ·Patrick Schöffski, Jos M Rooijackers, Agnieszka Woźniak, Jean‐Yves Blay, Sandra J. Strauss, Silvia Stacchiotti, Tomasz Świtaj, Veit Bücklein, Michael Leahy, Antoîne Italiano, Nicolás Isambert, Maria Dêbiec‐Rychter, Raf Sciot, E Minguez, Frank M. Speetjens, Axelle Nzokirantevye, Anouk Neven, Bernd Kasper	2021	38
4	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study British Journal of Cancer ·Hans Gelderblom, Robin L. Jones, Suzanne George, Pavan Bijalwan, Charlotte Benson, Jean-Yves Blay, Daniel J. Renouf, Toshihiko Doi, Axel Le Cesne, Michael Leahy, Sabine Hertle, Paola Aimone, Ulrike Brandt, Patrick Schöffski	2020	21
5	Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials Clinical Cancer Research ·Olivier Mir, Nathan Touati, Michela Lia, Saskia Litière, Axel Le Cesne, Stefan Sleijfer, Jean‐Yves Blay, Michael Leahy, Robin Young, Ron H.J. Mathijssen, Nielka P. van Erp, Hans Gelderblom, Winette T.A. van der Graaf, Alessandro Gronchi	2019	64
6	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 ‘CREATE’ European Journal of Cancer ·Patrick Schöffski, Agnieszka Woźniak, Michael Leahy, Steinar Aamdal, Piotr Rutkowski, Sebastian Bauer, Stephan Richter, Viktor Grünwald, Maria Dêbiec‐Rychter, Raf Sciot, Birgit Geoerger, Sandrine Marréaud, Sandra Collette, Axelle Nzokirantevye, Sandra J. Strauss	2018	32
7	Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma Clinical Cancer Research ·Ian Judson, Michelle Scurr, Kate Gardner, 金惠敏, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, Michael Leahy	2014	47
8	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials Annals of Oncology ·Axel Le Cesne, M. Ouali, Michael Leahy, Armando Santoro, Harald J. Hoekstra, Peter Hohenberger, Frits van Coevorden, Piotr Rutkowski, Alexander Markmann, Jaap Verweij, Sylvie Bonvalot, William P. Steward, Alessandro Gronchi, Pancras C.W. Hogendoorn, Saskia Litière, Sandrine Marréaud, Jean‐Yves Blay, Winette T.A. van der Graaf	2014	118
9	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas European Journal of Cancer ·Jean‐Yves Blay, Michael Leahy, Binh Bui Nguyen, Shreyaskumar Patel, Peter Hohenberger, Armando Santoro, Arthur P. Staddon, Nicolas Penel, Sophie Piperno‐Neumann, Andrew Hendifar, Pilar Lardelli, Antonio Nieto, Vicente Alfaro, Sant P. Chawla	2014	90
10	Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours British Journal of Cancer ·V.R. Bulusu, John Fullarton, Michael Leahy, Carys Morgan, J Sosna, Philippe Tanière, Simon Toh, Mark Verrill, Jeff White, Ian Judson	2013	5
11	PDB72 The Impact on Utilities of Weight Loss and Weight Gain Among Canadian Patients With Type 2 Diabetes Value in Health ·Susan Lane, Rosa Maria Marini Marioto, Jennifer Sambrook, Jayanti Mukherjee, Michael Leahy, Hugh D. Tildesley	2012	4
12	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SArcoma treatment and Burden of Illness in North America and Europe (SABINE) study Annals of Oncology ·Michael Leahy, Xavier García del Muro, Peter Reichardt, Ian Judson, Arthur P. Staddon, Jaap Verweij, Agnes Baffoe‐Bonnie, Linus Jönsson, Steven Tubagus, Nahila Justo, Thomas Burke, Jean‐Yves Blay	2012	56
13	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study Journal of Clinical Oncology ·Alberto S. Pappo, Shreyaskumar Patel, John Crowley, Denise K. Reinke, Klaus-Peter Kuenkele, Sant P. Chawla, Guy C. Toner, Robert G. Maki, Paul A. Meyers, Rashmi Chugh, Kristen N. Ganjoo, Scott M. Schuetze, Heribert Juergens, Michael Leahy, Birgit Geoerger, Robert S. Benjamin, Lee J. Helman, Laurence H. Baker	2011	252
14	Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986 Journal of Clinical Oncology ·Maria De Santis, Joaquim Bellmunt, Graham M. Mead, J. Martijn Kerst, Michael Leahy, Pablo Maroto, Iwona Skoneczna, Sandrine Marréaud, Ronald de Wit, Richard Sylvester	2009	123
15	A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992) Annals of Oncology ·Christine Théodore, Iwona Skoneczna, I. Bodrogi, Michael Leahy, J. Martijn Kerst, Laurence Collette, Katrin van der Ven, Sandrine Marréaud, Rebecca Oliver	2008	78
16	Phase III Trial of Two Investigational Schedules of Ifosfamide Compared With Standard-Dose Doxorubicin in Advanced or Metastatic Soft Tissue Sarcoma: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study Journal of Clinical Oncology ·Paul Lorigan, Jaap Verweij, Zsuzsa Pápai, Sjoerd Rodenhuis, Axel Le Cesne, Michael Leahy, John Radford, M. M. Van Glabbeke, Anne Kirkpatrick, Pancras C.W. Hogendoorn, Jean‐Yves Blay	2007	192
17	SCREAM - SuperCollider Resource for Electro-Acoustic Music. The Journal of the Abraham Lincoln Association ·Michael Leahy	2004	1
18	A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST) Sarcoma ·Ian Judson, Michael Leahy, Jeremy Whelan, Paul Lorigan, Mark Verrill, R. J. Grimer, Martin Robinson	2002	9
19	Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial British Journal of Cancer ·Justin S. Waters, A. Norman, David Cunningham, J.H. Scarffe, Andrew Webb, Peter Harper, Johnathan Joffe, Melanie Mackean, Janine Mansi, Michael Leahy, A Hill, J. Oates, Sheela Rao, M. Nicolson, Tamas Hickish	1999	221
20	Phase I study comparing continuous infusion of recombinant interleukin-2 by subcutaneous or intravenous administration European Journal of Cancer ·Michael Leahy, Jin-Guo Liu, Jiyuan An, C. Gallagher, R.T.D. Oliver	1992	11

About Michael Leahy

Michael Leahy is a scholar working on Gastroenterology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Rheumatology, having authored 70 papers that have together received 3.4k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (29 papers), Gastrointestinal Tumor Research and Treatment (17 papers), Vascular Tumors and Angiosarcomas (9 papers), Gastric Cancer Management and Outcomes (9 papers), Gastrointestinal disorders and treatments (7 papers), Cardiac tumors and thrombi (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). The work is most often cited by research in Oncology (1.8k citations), Pulmonary and Respiratory Medicine (2.0k citations), Gastroenterology (263 citations), Surgery (1.2k citations) and Rheumatology (367 citations). Michael Leahy has collaborated with scholars based in United Kingdom, France and Netherlands. Frequent co-authors include Sandrine Marréaud, Jean‐Yves Blay, J. Martijn Kerst, Jaap Verweij, Pancras C.W. Hogendoorn, Axel Le Cesne, Maria De Santis, Richard Sylvester, Pablo Maroto and Graham M. Mead. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, British Journal of Cancer and Sarcoma.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact